F. Fadzli, K. Rahmat, R. Muridan, Mohammad Nazri Mohd-Shah, O. Nawawi, C. Yip, L. Looi
Poster: "RANZCR ASM 2013 / R-0147 / Multimodal assessment of mammogram, ultrasound and clinical palpation in relation to pathological size of breast carcinoma" by: "F. Fadzli, K. Rahmat, R. Muridan, M. N. Mohd-Shah, O. Nawawi, C. H. Yip, L. M. Looi; Kuala Lumpur/MY"
海报:“RANZCR ASM 2013 / R-0147 /乳腺x线、超声和临床触诊与乳腺癌病理大小的多模态评估”，作者:F. Fadzli, K. Rahmat, R. Muridan, M. N. Mohd-Shah, O. Nawawi, C. H. Yip, L. M. Looi;吉隆坡/我”
{"title":"Multimodal assessment of mammogram, ultrasound and clinical palpation in relation to pathological size of breast carcinoma","authors":"F. Fadzli, K. Rahmat, R. Muridan, Mohammad Nazri Mohd-Shah, O. Nawawi, C. Yip, L. Looi","doi":"10.15761/ICST.1000267","DOIUrl":"https://doi.org/10.15761/ICST.1000267","url":null,"abstract":"Poster: \"RANZCR ASM 2013 / R-0147 / Multimodal assessment of mammogram, ultrasound and clinical palpation in relation to pathological size of breast carcinoma\" by: \"F. Fadzli, K. Rahmat, R. Muridan, M. N. Mohd-Shah, O. Nawawi, C. H. Yip, L. M. Looi; Kuala Lumpur/MY\"","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67474426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
P. Bastien, Neuzillet Yann, H. Eric, R. Morgan, Larre Stephane, P. Christian, Mottet Nicolas, Irani Jacques
Objective: The aim of this study was to evaluate health-related quality of life outcomes in patients who underwent orthotopic neobladder reconstruction (ONB) or ileal conduit (IC). Patients: Eight centers participated in this prospective study that included consecutive patients planned for radical cystectomy. Patients were asked to choose between IC or ONB reconstruction after thorough information. They had to complete the validated self-administered Bladder Cancer Index (BCI) preoperatively and again at 6 and 12 months after surgery as well as a set of questions exploring body image. Results: Among 106 patients who were invited to participate, 73 completed the preoperative questionnaires. In the preoperative phase, there were no significant differences in any of the QoL domains. At 6 months, 58 (61%) patients completed their questionnaires showing better functional scores in favor of IC in the urinary domain (P= 0.01). There was no other difference between groups. At 12 months, the findings were similar to those of the 6th month except for body image that was more favorable in ONB patients. VAS assessing diversion overall satisfaction was excellent in both groups despite a poor sexual satisfaction. Conclusions: Even if the results of this prospective non randomized study reflect partly the age difference between groups, they showed a better body image in ONB patients but a better urinary control for IC patients. In both groups, conversely to overall self-assessed satisfaction, sexual satisfaction was poor. *Correspondence to: Jacques Irani, Department of Urology, University Hospital of BICETRE, 94270 Le Kremlin-Bicetre, France, E-mail: jacques.irani@aphp.fr
目的:本研究的目的是评估接受原位新膀胱重建(ONB)或回肠导管(IC)患者的健康相关生活质量结果。患者:8个中心参与了这项前瞻性研究，包括计划进行根治性膀胱切除术的连续患者。在充分了解后，患者被要求选择IC或ONB重建。他们必须在术前和手术后6个月和12个月再次完成有效的自我管理膀胱癌指数(BCI)，以及一系列探索身体形象的问题。结果:106例入选患者中，73例完成术前问卷调查。在术前阶段，两组患者的生活质量均无显著差异。6个月时，58例(61%)患者完成问卷，显示尿域IC功能评分较高(P= 0.01)。两组之间没有其他差异。在12个月时，除了ONB患者的身体形象更有利外，结果与6个月时相似。VAS评估分流总体满意度在两组中都很好，尽管性满意度较差。结论:即使这项前瞻性非随机研究的结果部分反映了两组之间的年龄差异，但结果显示，ONB患者的身体形象更好，而IC患者的尿路控制更好。在这两组中，与总体自我评估满意度相反，性满意度较低。*通讯:Jacques Irani, BICETRE大学医院泌尿科，94270 Le kremin - BICETRE，法国，E-mail: jacques.irani@aphp.fr
{"title":"Prospective evaluation of quality-of-life outcomes following orthotopic neobladder and ileal conduit diversion after radical cystectomy","authors":"P. Bastien, Neuzillet Yann, H. Eric, R. Morgan, Larre Stephane, P. Christian, Mottet Nicolas, Irani Jacques","doi":"10.15761/icst.1000273","DOIUrl":"https://doi.org/10.15761/icst.1000273","url":null,"abstract":"Objective: The aim of this study was to evaluate health-related quality of life outcomes in patients who underwent orthotopic neobladder reconstruction (ONB) or ileal conduit (IC). Patients: Eight centers participated in this prospective study that included consecutive patients planned for radical cystectomy. Patients were asked to choose between IC or ONB reconstruction after thorough information. They had to complete the validated self-administered Bladder Cancer Index (BCI) preoperatively and again at 6 and 12 months after surgery as well as a set of questions exploring body image. Results: Among 106 patients who were invited to participate, 73 completed the preoperative questionnaires. In the preoperative phase, there were no significant differences in any of the QoL domains. At 6 months, 58 (61%) patients completed their questionnaires showing better functional scores in favor of IC in the urinary domain (P= 0.01). There was no other difference between groups. At 12 months, the findings were similar to those of the 6th month except for body image that was more favorable in ONB patients. VAS assessing diversion overall satisfaction was excellent in both groups despite a poor sexual satisfaction. Conclusions: Even if the results of this prospective non randomized study reflect partly the age difference between groups, they showed a better body image in ONB patients but a better urinary control for IC patients. In both groups, conversely to overall self-assessed satisfaction, sexual satisfaction was poor. *Correspondence to: Jacques Irani, Department of Urology, University Hospital of BICETRE, 94270 Le Kremlin-Bicetre, France, E-mail: jacques.irani@aphp.fr","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67474564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
O. Prokopchuk, Santiago Moreno-Ordaz, N. Hüser, Jeannine Bachmann, B. Konukiewitz, Andrea Delgado-Picolomini, H. Friess, M. Martignoni
{"title":"Unusual coexistence of Ménétrier disease with adenocarcinoma of the esophagogastric junction: A case report and review of the literature","authors":"O. Prokopchuk, Santiago Moreno-Ordaz, N. Hüser, Jeannine Bachmann, B. Konukiewitz, Andrea Delgado-Picolomini, H. Friess, M. Martignoni","doi":"10.15761/ICST.1000277","DOIUrl":"https://doi.org/10.15761/ICST.1000277","url":null,"abstract":"","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"104 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67474834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Nagashima, Ayako Hiranuma, T. Oshiro, Yu Sato, Tomoaki Kitahara, T. Nabekura, Y. Moriyama, Motoaki Arai, M. Ando, Kengo Kadoya, Ayami Sato, K. Kawamitsu, R. Takagi, T. Urita, Y. Yoshida, Hiroshi Tanaka, S. Okazumi
Oxaliplatin is a platinum-based cytotoxic chemotherapeutic agent, and is usually used in combination; as part of the FOLFOX regimen, to treat advanced colorectal cancer (CRC) patients. However, oxaliplatin produces significant chemotherapy-induced peripheral neuropathy (CIPN), a potential dose-limiting side effect of treatment. Preventive and therapeutic protocol for oxaliplatin-induced peripheral neuropathy (OIPN) has not yet been established. Previously, we reported that controlled-release oxycodone (CR oxycodone) attenuated the pain of OIPN and extended FOLFOX therapy in advanced CRC patients. We further investigated the efficacy of CR oxycodone for OIPN and its association with patients’ survival time. This was a retrospective analysis of advanced CRC patients. A total of 64 patients with stage III or IV CRC were included in this study. All patients underwent surgery to extirpate the primary CRC and received curative-intent FOLFOX chemotherapy. Patients who were administered CR oxycodone during the FOLFOX therapy period were defined as the OXY group (29 cases), and those who did not receive CR oxycodone treatment were defined as the non-OXY group (35 cases). Survival time was calculated using the Kaplan-Meier method to determine differences between patients in the OXY and the non-OXY groups. Patients in the OXY group had relatively longer survival than those in the non-OXY group (median survival, 58 months vs. 36 months; P=0.06). Early administration of CR oxycodone for OIPN might be relatively effective for better patient compliance with FOLFOX chemotherapy, a better QOL, and longer survival in patients with advanced CRC. *Correspondence to: Makoto Nagashima, Department of Surgery, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura 285-8741, Japan, Tel: +81-43-462-8811, Fax: +81-43-463-1456, E-mail: nagashima@sakura.med. toho-u.ac.jp
{"title":"Survival difference associated with controlled-release oxycodone analgesic therapy for oxaliplatin-induced peripheral neuropathy in advanced colorectal cancer patients","authors":"M. Nagashima, Ayako Hiranuma, T. Oshiro, Yu Sato, Tomoaki Kitahara, T. Nabekura, Y. Moriyama, Motoaki Arai, M. Ando, Kengo Kadoya, Ayami Sato, K. Kawamitsu, R. Takagi, T. Urita, Y. Yoshida, Hiroshi Tanaka, S. Okazumi","doi":"10.15761/ICST.1000289","DOIUrl":"https://doi.org/10.15761/ICST.1000289","url":null,"abstract":"Oxaliplatin is a platinum-based cytotoxic chemotherapeutic agent, and is usually used in combination; as part of the FOLFOX regimen, to treat advanced colorectal cancer (CRC) patients. However, oxaliplatin produces significant chemotherapy-induced peripheral neuropathy (CIPN), a potential dose-limiting side effect of treatment. Preventive and therapeutic protocol for oxaliplatin-induced peripheral neuropathy (OIPN) has not yet been established. Previously, we reported that controlled-release oxycodone (CR oxycodone) attenuated the pain of OIPN and extended FOLFOX therapy in advanced CRC patients. We further investigated the efficacy of CR oxycodone for OIPN and its association with patients’ survival time. This was a retrospective analysis of advanced CRC patients. A total of 64 patients with stage III or IV CRC were included in this study. All patients underwent surgery to extirpate the primary CRC and received curative-intent FOLFOX chemotherapy. Patients who were administered CR oxycodone during the FOLFOX therapy period were defined as the OXY group (29 cases), and those who did not receive CR oxycodone treatment were defined as the non-OXY group (35 cases). Survival time was calculated using the Kaplan-Meier method to determine differences between patients in the OXY and the non-OXY groups. Patients in the OXY group had relatively longer survival than those in the non-OXY group (median survival, 58 months vs. 36 months; P=0.06). Early administration of CR oxycodone for OIPN might be relatively effective for better patient compliance with FOLFOX chemotherapy, a better QOL, and longer survival in patients with advanced CRC. *Correspondence to: Makoto Nagashima, Department of Surgery, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura 285-8741, Japan, Tel: +81-43-462-8811, Fax: +81-43-463-1456, E-mail: nagashima@sakura.med. toho-u.ac.jp","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67475107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Muscarinic acetylcholine receptors (mAChRs) belong to the G protein coupled receptor group (GPCRs) and together with nicotinic receptors formed the cholinergic receptor family [1]. Both types of receptors respond to acetylcholine but trigger different signaling pathways since the first one exerts metabotropic actions while the latter is ionotropic. Several authors reported the expression of mAChRs in tumor cells and tissues [2]. Five subtypes of mAChRs (M1-M5) have been cloned. Their activation by acetylcholine triggers not only the activation of classical signal transduction pathways like phospholipase C/inositol trisphophate/calcium for M1, M3 and M5 subtypes and the inhibition of adenylyl cyclase for M2 and M4 subtypes; but may activate also non-canonical signals like Ras-Raf-1-Erk-AKT for M3 receptor subtype [1,3].
{"title":"Breast cancer: Metronomic therapy focused on muscarinic acetylcholine receptors","authors":"M. Sales","doi":"10.15761/ICST.1000291","DOIUrl":"https://doi.org/10.15761/ICST.1000291","url":null,"abstract":"Muscarinic acetylcholine receptors (mAChRs) belong to the G protein coupled receptor group (GPCRs) and together with nicotinic receptors formed the cholinergic receptor family [1]. Both types of receptors respond to acetylcholine but trigger different signaling pathways since the first one exerts metabotropic actions while the latter is ionotropic. Several authors reported the expression of mAChRs in tumor cells and tissues [2]. Five subtypes of mAChRs (M1-M5) have been cloned. Their activation by acetylcholine triggers not only the activation of classical signal transduction pathways like phospholipase C/inositol trisphophate/calcium for M1, M3 and M5 subtypes and the inhibition of adenylyl cyclase for M2 and M4 subtypes; but may activate also non-canonical signals like Ras-Raf-1-Erk-AKT for M3 receptor subtype [1,3].","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67475322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Glioblastoma (GBM) remains an incurable disease with a poor overall survival. Despite extensive research into clinical trials, temozolomide remains the only therapeutic agent to improve patient survival in the past 50 years. This is despite only providing a modest increase of 2.5 months to median survival. Resistance to traditional therapies has become a hallmark of GBM, owing to its complex and undetermined molecular landscape. Studies now suggest that GBM is a disease of genetic subtypes and require tailored approaches to therapeutic care. Further strategies for GBM treatment involve targeting tumour associated neovascularisation. While early attempts to attenuate the tumour vascularisation with anti-VEGF has not been successful, studies are now looking towards other angiogenic factors and novel mechanisms of neovascularisation that have yet to be explored. A shift towards understanding the molecular and biological mechanisms of GBM pathogenesis represents a promising new strategy for treatment. Here we highlight some of the major developments to genetic profiling and anti-neovascularisation therapy.
{"title":"Glioblastoma treatment: Where to now?","authors":"T. Ware, Hong-Jian Zhu","doi":"10.15761/icst.1000280","DOIUrl":"https://doi.org/10.15761/icst.1000280","url":null,"abstract":"Glioblastoma (GBM) remains an incurable disease with a poor overall survival. Despite extensive research into clinical trials, temozolomide remains the only therapeutic agent to improve patient survival in the past 50 years. This is despite only providing a modest increase of 2.5 months to median survival. Resistance to traditional therapies has become a hallmark of GBM, owing to its complex and undetermined molecular landscape. Studies now suggest that GBM is a disease of genetic subtypes and require tailored approaches to therapeutic care. Further strategies for GBM treatment involve targeting tumour associated neovascularisation. While early attempts to attenuate the tumour vascularisation with anti-VEGF has not been successful, studies are now looking towards other angiogenic factors and novel mechanisms of neovascularisation that have yet to be explored. A shift towards understanding the molecular and biological mechanisms of GBM pathogenesis represents a promising new strategy for treatment. Here we highlight some of the major developments to genetic profiling and anti-neovascularisation therapy.","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67474711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Proteogenomics is the field of integrating data from mass spectrometry-based shotgun proteomics, and phosphoproteomics into next-generation RNA and DNA sequencing data analysis pipelines that promises new insights into cancer biology and therapeutic targeting. As well as analyses of clinical samples for disease phenotype association analysis, the application of proteogenomics to model systems also has considerable potential. Patient-derived xenografts (PDX) generated in immunosuppressed mice strains provide a useful setting to analyze the biological properties of the intrinsic subtypes of breast cancer because this approach effectively captures the biological diversity of this disease [1]. The Clinical Proteomic Tumor Analysis Consortium (CPTAC) generated quantitative i-TRAQ mass spectrometry-based proteomics and phosphoproteomics data across the WHIM series of PDXs tumors that was combined with RNA and DNA sequencing information to provide integrated proteogenomic profiles [2]. Herein we explored these data to identify extreme outliers in the proteogenomic data that were Claudin-low (CLOW) subtype-specific and had not previously studied in breast cancer. WHIM12 breast cancer PDX was previously classified as a high confidence CLOW tumor based on transcriptomic profiling [2]. A CPTAC proteogenomic analysis prioritized dihydropyrimidinaselike-3 (DPYSL3) as a multi-level (RNA/Protein/Phosphoprotein) expression outlier specific to the CLOW subset of triple negative breast cancers. These data suggested high-levels of DPYSL3 expression and hyper-phosphorylation were associated with CLOW breast cancer and thus DPYSL3 may regulate some of the unique biological features of this subtype. In our view, discovery approaches that trangulate multiple tiers of ‘omics data with literature search engines to identify novel and targetable cancer biology should be more widely applied.
{"title":"DPYSL3 is a mutifunctional modulator in claudin-low breast cancer","authors":"Ryoichi Matsunuma, M. Ellis","doi":"10.15761/icst.1000294","DOIUrl":"https://doi.org/10.15761/icst.1000294","url":null,"abstract":"Proteogenomics is the field of integrating data from mass spectrometry-based shotgun proteomics, and phosphoproteomics into next-generation RNA and DNA sequencing data analysis pipelines that promises new insights into cancer biology and therapeutic targeting. As well as analyses of clinical samples for disease phenotype association analysis, the application of proteogenomics to model systems also has considerable potential. Patient-derived xenografts (PDX) generated in immunosuppressed mice strains provide a useful setting to analyze the biological properties of the intrinsic subtypes of breast cancer because this approach effectively captures the biological diversity of this disease [1]. The Clinical Proteomic Tumor Analysis Consortium (CPTAC) generated quantitative i-TRAQ mass spectrometry-based proteomics and phosphoproteomics data across the WHIM series of PDXs tumors that was combined with RNA and DNA sequencing information to provide integrated proteogenomic profiles [2]. Herein we explored these data to identify extreme outliers in the proteogenomic data that were Claudin-low (CLOW) subtype-specific and had not previously studied in breast cancer. WHIM12 breast cancer PDX was previously classified as a high confidence CLOW tumor based on transcriptomic profiling [2]. A CPTAC proteogenomic analysis prioritized dihydropyrimidinaselike-3 (DPYSL3) as a multi-level (RNA/Protein/Phosphoprotein) expression outlier specific to the CLOW subset of triple negative breast cancers. These data suggested high-levels of DPYSL3 expression and hyper-phosphorylation were associated with CLOW breast cancer and thus DPYSL3 may regulate some of the unique biological features of this subtype. In our view, discovery approaches that trangulate multiple tiers of ‘omics data with literature search engines to identify novel and targetable cancer biology should be more widely applied.","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67475170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Received: March 11, 2018; Accepted: March 29, 2018; Published: April 02, 2018 An RNA-binding protein, Musashi-1 (Msi1), is a posttranscriptional gene regulator that is involved in the regulation of stem cell self-renewal. Because of its high-level expression in neural stem cells (NSCs) and undifferentiated neural precursor cells [1], Msi1 is used as a cell marker for NSCs and progenitor cells in the central nervous system. Increasing evidence suggested that Mis1 acts as a critical regulator of the status of stem/progenitor cells in other tissues and organs [2,3], including the breast, eye, hair follicles, intestine, and stomach, in either embryonic or adult stages; thus, Msi1 may also be used as an effective marker for stem/progenitor cells in a wide range of tissues and organs.
{"title":"Utilizing NMR to study RNA- and compound-binding mechanisms of Musashi-1, a stem/progenitor cell marker in various normal and cancer cells","authors":"T. Nagata","doi":"10.15761/ICST.1000269","DOIUrl":"https://doi.org/10.15761/ICST.1000269","url":null,"abstract":"Received: March 11, 2018; Accepted: March 29, 2018; Published: April 02, 2018 An RNA-binding protein, Musashi-1 (Msi1), is a posttranscriptional gene regulator that is involved in the regulation of stem cell self-renewal. Because of its high-level expression in neural stem cells (NSCs) and undifferentiated neural precursor cells [1], Msi1 is used as a cell marker for NSCs and progenitor cells in the central nervous system. Increasing evidence suggested that Mis1 acts as a critical regulator of the status of stem/progenitor cells in other tissues and organs [2,3], including the breast, eye, hair follicles, intestine, and stomach, in either embryonic or adult stages; thus, Msi1 may also be used as an effective marker for stem/progenitor cells in a wide range of tissues and organs.","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67474584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Absolute digital(d)PCR quantification of micro(mi)RNA molecules for the diagnostic screening of colon cancer in human stool: A methodological review","authors":"F. Ahmed, Nancy C. Ahmed, M. Gouda","doi":"10.15761/icst.1000297","DOIUrl":"https://doi.org/10.15761/icst.1000297","url":null,"abstract":"","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67475231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
O. E. Jouari, S. Elloudi, G. Senhaji, A. L. Mimi, Z. Douhi, H. Baybay, M. Rimani, F. Mernissi
{"title":"A particular dubrheuil melanoma","authors":"O. E. Jouari, S. Elloudi, G. Senhaji, A. L. Mimi, Z. Douhi, H. Baybay, M. Rimani, F. Mernissi","doi":"10.15761/icst.1000295","DOIUrl":"https://doi.org/10.15761/icst.1000295","url":null,"abstract":"","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67475189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：